# <sup>1</sup>**The Dynamic Genetic Atlas of 122 Gestational**

## <sup>2</sup>**Phenotypes**

- 3
- 4 Siyang Liu<sup>1\*#</sup>, Hao Zheng<sup>1,2,3\*</sup>, Yuqin Gu<sup>1,3\*</sup>, Zijing Yang<sup>1,2\*</sup>, Yanhong Liu<sup>1</sup>, Yuandan
- 5 Wei<sup>1,3</sup>, Xinxin Guo<sup>1</sup>, Yanchao Chen<sup>1</sup>, Liang Hu<sup>2</sup>, Xiaohang Chen<sup>2</sup>, Fuquan Zhang<sup>3</sup>,
- 6 Guo-Bo Chen<sup>4</sup>, Xiu Qiu<sup>5</sup>, Shujia Huang<sup>5#</sup>, Jianxin Zhen<sup>3#</sup>, Fengxiang Wei<sup>2,6#</sup>
- <sup>7</sup>1. School of Public Health (Shenzhen), Sun Yat-sen University, Shenzhen,
- 8 Guangdong 518107, China
- <sup>9</sup>2. The Genetics Laboratory, Longgang District Maternity and Child Healthcare
- 10 Hospital of Shenzhen City, Shenzhen, Guangdong, 518172, China
- <sup>11</sup>3. Central Laboratory, Shenzhen Baoan Women's and Children's Hospital, Shenzhen,
- 12 Guangdong 518102, China
- <sup>13</sup>4. Center for Productive Medicine, Department of Genetic and Genomic Medicine,
- <sup>14</sup>Clinical Research Institute, Zhejiang Provincial People's Hospital, People's
- 15 Hospital of Hangzhou Medical College, Hangzhou 310014, Zhejiang, China
- 16 5. Division of Birth Cohort Study, Guangzhou Women and Children's Medical Center,
- 17 Guangzhou Medical University, Guangzhou, 510623, China
- <sup>18</sup>6. Longgang Maternity and Child Institute of Shantou University Medical College,
- 19 Shenzhen, Guangdong, 518172, China
- 20  $*$ : Those authors contribute equally as co-first authors
- 21 #: Correspondence can be addressed to

- 22 Siyang Liu liusy99@mail.sysu.edu.cn
- 23 Shujia Huang shujia.huang@bigcs.org
- 24 Jianxin Zhen jxzhen@qq.com
- 25 Fengxiang Wei haowei727499@163.com
- 26

### <sup>27</sup>**Abstract**

28 The gestational period, spanning approximately 40 weeks from fertilization to birth, is 29 pivotal in human reproduction. Monitoring the health of pregnant women and 30 newborns during this period involves systematic prenatal and postpartum 31 examinations, guided by indicators established under the national medical insurance 32 system, collectively termed gestational phenotypes. However, our understanding of 33 the genetic basis of these phenotypes and their intricate relationship with maternal 34 long-term health outcomes remain markedly limited. We conducted comprehensive 35 genetic investigations into 122 gestational phenotypes among 121,579 Chinese 36 pregnancies. These phenotypes included anthropometric metrics, comprehensive 37 blood biomarker measurements, and common gestational complications and outcomes. <sup>38</sup>We identified 3,845 genetic loci, 1,385 of which are novel. Our analyses revealed 39 gestation-specific genetic effects, ranging from proportion 0% to 100% for 23 40 phenotypes, highlighting genes and pathways predominantly enriched in response to 41 hormones, growth and immune function. Longitudinal trajectory genome-wide 42 association study (GWAS) analyses of repeated measures across 24 complete blood 43 cell phenotypes revealed that 17.8% of the genetic variants exhibited significant 44 interactions with gestational timing across five gestational and postpartum periods. <sup>45</sup>Two-sample univariable and multivariable Mendelian Randomization (MR) analyses 46 of 220 mid- and old-age phenotypes suggested causal associations between 47 gestational phenotypes and the risk of chronic diseases in later life. These findings 48 provide initial insights into the genetic foundations of human gestational phenotypes 49 and their relationship with long-term health, laying a basis for advanced population 50 health during gestation. 51

52

## <sup>53</sup>**Introduction**

54 Women's reproductive, maternal, newborn, child, and adolescent health are 55 fundamental aspects of human health development and the key drivers of future 56 population and social progress<sup>1,2</sup>. Amid the global trends of population aging and 57 declining fertility rates<sup>3,4</sup>, maternal and child health has increasingly emerged as a 58 critical global public health concern. Particularly noteworthy is the gestational period, 59 starting from fertilization, to birth over approximately 40 weeks, is a crucial phase 60 during which the developing organism undergoes substantial growth and 61 differentiation, while the pregnant individual experiences various physiological 62 changes to support the fetus<sup>5,6</sup>. Given the importance of this period, the health of 63 pregnant women and newborns is monitored through a set of systematic and timed 64 prenatal and postpartum examinations manipulated via the national medical insurance 65 system. These indicators encompass anthropometric metrics, a series of blood and 66 urine measurements and prenatal tests, forming the basis for diagnosing pregnancy 67 disorders and forecasting birth outcomes, collectively making up the gestational 68 phenotypes (**Fig. 1 and Supplementary Table 1**). 69 70 Despite the critical nature of the gestation period, the genetic underpinnings 71 underlying the gestational phenotypes and their connections to later age health 72 outcomes remain poorly understood. Of the 122 gestational phenotypes, only 29 have <sup>73</sup>been explored in previous GWAS studies (**Supplementary Table 1**), and 11 were 74 part of our earlier work<sup>7-9</sup>. While extensive genetic studies have been conducted on a 75 variety on various quantitative phenotypes in the general population  $10,11$ , few have 76 addressed the distinct genetic basis of phenotypes during the gestation<sup>8,9,12</sup>, and the 77 time-dependent genetic effects during this period remain largely unknown. <sup>78</sup>Additionally, despite observational studies have linked gestational status to maternal 79 older age health status<sup>13-16</sup>, evaluations of the causal effects of the spectrum of

80 gestational phenotypes, which usually collected earlier in life, on later age health

81 status have not yet been achieved, hindering the potential for early screening of

- 82 diseases for women typically aged 20 to 40.
- 83

84 To address this gap, we collected data on 122 prenatal and postnatal screening 85 indicators and non-invasive prenatal test (NIPT) sequencing data from 121,579 86 unrelated pregnant women (mean age  $30 \pm 4$ ). We posed the following questions: (1) 87 What are the genetic determinants for these gestational phenotypes and what is their 88 heritability? (2) Do pregnancy-specific genetic effect exit, and which genes exhibit 89 these effects? (3) Are there gene-by-environment ( $G \times E$ ) interactions for the genetic 90 loci associated with gestational phenotypes? (4) What are the causal relationships 91 between gestational phenotypes and maternal long-term health? To address these 92 questions, we conducted a large-scale genome-wide association study (GWAS) using 93 our developed analytical protocol<sup>7,17</sup>, constructing an atlas of quantitative and 94 qualitative trait loci and replicating our findings in external cohorts. We investigated 95 patterns of genetic loci with differential effects during pregnancy and non-pregnancy 96 using a Bayesian clustering algorithm, and examined  $G \times E$  effects through repeated 97 sampling of the same phenotypes during pregnancy using regression models. Finally, 98 we used our atlas to estimate potential causal relationships between gestational 99 phenotypes and 220 phenotypes in BioBank Japan (mean age 63 years), mimicking an 100 impact of the gestational phenotypes over the long-term health outcomes<sup>10</sup> (**Fig. 1**). 101

#### <sup>102</sup>**Results**

### <sup>103</sup>**Study design**

<sup>104</sup>We collected NIPT sequencing data and 122 comprehensive pregnancy screening 105 measurements, including biomarkers and electronic medical records, from 121,579 106 Chinese pregnancies who participated in routine obstetric examinations at two 107 hospitals in Shenzhen City. We categorized the 88 gestational phenotypes into nine 108 molecular test categories: Blood lipid (N=2), Glycemic (N=6), Blood routine (N=32),



- 110 screening  $(N=16)$  and NIPT screening  $(N=3)$  (**Fig.1, Supplementary Table 2**).
- 111 Additionally, we included 34 phenotypes in three categories of electronic medical
- 112 records: Basic information such as maternal height, weight, blood pressure  $(N=7)$ ,
- <sup>113</sup>Gestational disorders (N=21) and Birth outcomes (N=6) (**Fig. 1, Supplementary**
- <sup>114</sup>**Table 3**). Sample sizes for each phenotype ranged from 12,024 (gestational diabetes
- 115 mellitus with medication in Glycemic) to 115,872 (trisomy 18 risk score in NIPT
- 116 screening). The distribution of all quantitative gestational phenotypes and the

117 prevalence of common gestational comorbidities were highly consistent between the

118 two hospitals (**Supplementary Table 4-5, Supplementary Fig. 1-2**).

119

120 All participants underwent NIPT as part of standard prenatal screening in Shenzhen.

121 We applied our estimated protocol to infer and impute genotypes, estimate family-

122 relatedness, infer population structure, and conduct GWAS. More details about the

123 analyses are provided in the **Methods** section.

124

#### <sup>125</sup>**3,845 genetic associations with 122 gestational phenotypes**

126 Using the collected phenotype data and NIPT genotypes, we performed GWAS for

127 the 122 gestational phenotypes from Baoan and Longgang hospitals, respectively,

128 followed by a fixed-effect meta-analysis across 12.6 million genetic markers

<sup>129</sup>(**Supplementary Table 6**). Linkage disequilibrium (LD) score intercepts were

<sup>130</sup>between 0.94 and 1.10 for all 122 phenotypes (**Supplementary Table <sup>7</sup>**), which

131 suggested that population structure in our analysis was well controlled. Besides the

- 132 conventional genome-wide significant threshold  $(P < 5 \times 10^{-8})$ , we set a stricter study-
- 133 wide significant threshold to  $P = 4.1 \times 10^{-10} (P < 5 \times 10^{-8}/122)$  after Bonferroni
- 134 correction for multiple testing. After GCTA conditional and joint analysis<sup>18</sup>, we
- 135 identified 4,309 independent signals in 3,242 loci associated with at least one
- 136 phenotypes  $(P<sub>5</sub>×10<sup>-8</sup>)$  among nine categories (**Supplementary Table 8**), where

137 2,942 signals in 1,999 loci reached study-wide significance  $(P<4.1\times10^{-10})$  (**Fig. 2,** 

<sup>138</sup>**Supplementary Table 9**). The highest number of loci were found in the blood routine 139 category among all the categories, and the phenotype with the highest number of loci <sup>140</sup>was platelet-large cell ratio (P\_LCR) (**Fig. 2, Supplementary Table 9**). Within the 141 three categories of basic information, birth outcomes and gestational disorders, we found 367 independent signals in 279 loci  $(P < 4.1 \times 10^{-10})$  and 718 independent 143 signals in 603 loci  $(P < 5 \times 10^{-8})$  (**Supplementary Table 10-11**). 144 145 Genetic effect estimations are highly consistent between the two hospitals with 146 squared Pearson's correlation coefficient  $R^2$  greater than 0.76 for nine categories of 147 quantitative traits and  $R^2$  greater than 0.12 for three categories of qualitative traits <sup>148</sup>(**Supplementary Fig. 3**). Only 369 out of 4,309 (8.5%) loci associated with the nine 149 categories of gestational phenotypes and 74 out of 718 (10.3%) associated with the 150 three categories of gestational phenotypes exhibited statistical heterogeneity 151  $(P_{\text{het}} < 0.05)$  (**Supplementary Table 8-11**). We also performed two replication studies 152 comparing genetic effect estimates with independent cohorts to evaluate the 153 robustness of effect estimates in our study. In replication study I, assuming maternal 154 height is not influenced by a gestational status, we compared genetic effect estimates 155 of maternal height-associated variants with that estimated in the Taiwan Biobank with 156 the GWAS summary statistic for maternal height in this study<sup>19</sup>. The genetic effect 157 estimates are highly consistent between our study and the Taiwan Biobank study with 158  $R^2 = 0.93$  (**Supplementary Fig. 4**). There were 121 variants with *P* values less than 159 the Bonferroni correction threshold  $(P < 2.79 \times 10^{-4}$ , 66.9%), and 166 variants with *P* <sup>160</sup>value less than 0.05 (91.7%) (**Supplementary Fig. 4, Supplementary Table 12**). In 161 replication study II, we compared the genetic effects with an independent cohort 162 (NIPT PLUS pregnancy cohort), which is our additional collection of maternal check-<sup>163</sup>up data from 5,733 pregnant women (**Methods**). Using *two-sample t-test*, 4,059 of the

164 4,804 variants of the 103 phenotypes with data in NIPT PLUS cohort had consistent

- <sup>165</sup>genetic effect size in independent cohort (84.5%) (**Supplementary Fig. 5**,
- <sup>166</sup>**Supplementary Table 13**). Of the 3,198 variants that were study-wide significance
- 167 within the study, 2,786 variants had consistent genetic effect (87.1%)
- <sup>168</sup>(**Supplementary Table 13**). The above results indicate high fidelity of the GWAS
- 169 findings and genetic effect estimates in this study.
- 170

#### <sup>171</sup>**1,385 novel genetic associations**

- 172 Among the 122 gestational phenotypes, 29 were previously investigated among
- 173 pregnant women and 70 were investigated in the general populations
- **174** (**Supplementary Table 1**). After comparison with the GWAS Catalog<sup>20</sup> of previously
- 175 reported associations with the same or similar phenotypes in either the pregnant or the
- <sup>176</sup>general populations (**Methods**), 1,189 of the 3,242 loci surpassing the genome-wide
- 177 threshold (**Supplementary Table 8**), and 651 of the 1,999 loci surpassing the study-
- <sup>178</sup>wide threshold were novel among nine categories (**Supplementary Table 9**). Among
- 179 the three categories, 196 of the 603 loci surpassing the genome-wide threshold, as
- 180 well as 64 of the 279 loci surpassing the study-wide threshold were novel
- <sup>181</sup>(**Supplementary Table 10-11**). Notably, 5,483 and 5,194 functional variants
- 182 including missense and nonsense variants  $(P < 5 \times 10^{-8})$  were found for the 3,242
- 183 genome-wide significant loci and the 1,999 study-wide significant loci  $(P < 4.1 \times 10^{-10})$ ,
- <sup>184</sup>respectively (**Supplementary Table 14-15**). 256 study-wide newly discovered loci
- 185 with at least one functional variant were illustrated in Fig. 2.
- 186
- 187 Among the 651 study-wide significant novel loci associated with the nine
- 188 quantitative trait categories, 114 were associated with multiple gestational
- 189 phenotypes (**Supplementary Table 16**). The genes mapped in these 114
- 190 pleiotropic loci were significantly enriched in GO pathway such as response to
- 191 hormones, compared to an enrichment of more basic celluar processes such as
- 192 hemostasis, regulation of cell-cell adhension for genes without pleiotropy



216 studied, such as the screening phenotypes for fetal trisomy. Combined maternal

- 217 serum Tang and NIPT screening along with fetal ultrasound testing are used to
- 218 screen for the risk of fetal trisomy<sup>24,25</sup>, so these phenotypes are essential for the
- 219 gestational period. For the NIPT screening scores for T21, T18 and T13, we found
- 220 26, 35 and 31 quantitative trait loci  $(P < 4.1 \times 10^{-10})$  (**Supplementary Table 9,**



**Table 18-19,**). The two heatmaps were basically symmetric along the red diagonal

249 line suggesting that substantial phenotypic variability derived from the genetic

250 variability (**Supplementary Fig. 11**). Tightly correlated phenotypic domains were

251 clustered within categories, while significant and strong genetic correlations also

252 occur across categories.

253

### <sup>254</sup>**Gestation-specific genetic effect**

255 Gestational phenotypes may exhibit pregnancy-specific genetic effects distinct from 256 the same phenotypes outside pregnancy. For 23 out of the 122 phenotypes 257 investigated, including maternal height, we obtained GWAS data in a non-pregnant 258 cohort from the Taiwan Biobank ( $n = 92,615$ , age 30-70, southern Chinese ancestry) 259. <sup>19</sup>. Genetic correlations for the same phenotype between the two datasets are all 260 significant ranging from 0.18 to 0.94 (**Supplementary Table 20**). Correlations of 261 genetic effect of NIPT lead SNPs are high between our study and the Taiwan Biobank 262 study with genetic effect  $R^2$  ranging from 0.001 to 0.99 (**Supplementary Fig. 12,** 

<sup>263</sup>**Supplementary Table 21**). 900 genetic signals were present with study-wide

264 significance for the 23 phenotypes and 792 signals have genetic effect information in

265 both our and the Taiwan studies (**Supplementary Table 22**).

266

267 We then applied a Bayesian clustering algorithm<sup>36</sup> combined with colocalization 268 analysis to explore whether there exists genetic effects that are predominantly 269 influenced by pregnancy compared to non-pregnancy population. Model parameters 270 are detailed in **Supplementary Table 23 and Methods.** Genetic loci associated with 271 each of the gestational trait were categorized into two groups: general and pregnancy-272 specific, with the remaining loci denoted as unclassified. In total, we have identified <sup>273</sup>138 genetic signals exhibiting pregnancy specific genetic effects (**Supplementary Fig.**  <sup>274</sup>**13, Supplementary Table 24**). The general variants indicates that the genetic effects 275 were shared with non-pregnancy phenotypes, and pregnancy-specific cluster indicates 276 the ones dominated by mainly gestational phenotypes. In total, we found 138 out of

277 the 792 signals exhibiting pregnancy-specific effects (17.4%), while 381 signals 278 demonstrating shared genetic effect (48.1%) and 273 remains uncertain (34.5%). 279 When ranking these 23 phenotypes by the proportion of pregnancy-specific loci 280 among all loci, alpha fetoprotein levels (AFP\_S2) or its adjusted form, the alpha-281 fetoprotein multiples-of-median (AFPMOM S2) in second trimester screening have 282 the highest proportion of variants exhibiting pregnancy-specific genetic effects, 283 followed by two biomarkers for liver function including alanine transaminase (ALT) 284 and albumin (ALB) (**Fig. 3A, Supplementary Table 24**). Contrastly, the lowest 285 proportion of pregnancy specific variants were observed for maternal height and first 286 systolic blood pressure measurements, consistent with our perception that pregnant 287 women's height is largely unchanged during pregnancy and blood pressure stays 288 stable in early pregnancy.

289

290 Pathway enrichment analyses of the pregnancy-specific, general and overall genetic 291 loci were summarized in **Supplementary Fig. 14**. We further conducted a pathway 292 enrichment analyses using genes falling within the pregnancy-specific effect and the 293 general effect clusters to test whether some pathways may significantly differ between 294 the two clusters of genes (two-tailed chisq or fisher exact test,  $P < 0.05$ ) (**Fig. 3B,** <sup>295</sup>**Supplementary Table 25)**. Among these top 20 significant pathways for the 296 pregnancy-specific genetic loci, there are a variety of pathways that have significantly 297 different gene proportion on both sides, such as the retinoid metabolism and transport, 298 Wnt signaling pathway and pluripotency and regulation of protein catabolic process 299 that only contains pregnancy-specific loci (**Fig. 3B**). In addition, pathways that 300 demonstrated nominally significance include GO pathways of responses to hormone, 301 glucose homeostasis and regulation of lymphocyte proliferation; KEGG pathways of 302 breast cancer, WikiPathways of pathways in cancer and adipogenesis and Reactome <sup>303</sup>gene sets of signaling by nuclear receptors (**Supplementary Table 25**). PPI network 304 hub gene analyses weighting the genes by degree suggests that the most

305 distinguishing hub genes are similar to the genes that were associated with multiple 306 gestational phenotypes, including the estrogen receptor (*ESR1*), insulin like growth <sup>307</sup>factor 1 (*IGF1*) and interleukin 6 (*IL6*) (**Supplementary Fig. 15, Supplementary**  <sup>308</sup>**Table 26**). These findings suggests that hormone, growth and development mediators 309 and immune regulations are playing an essential role for starting the gestation process. 310 <sup>311</sup>**G (genetics) by T (time) interaction across gestation and postpartum**  <sup>312</sup>**period**  <sup>313</sup>Among the 122 gestational phenotypes, the 24 phenotypes belonging to the blood 314 routine category assayed by the complete blood count (CBC)  $37,38$  are repeatedly 315 assayed for a median number of 5 to 6 measurements in each of the two hospitals <sup>316</sup>(**Supplementary Fig. 16-17, Supplementary Table 27**), offering us an opportunity 317 to understand the patterns and biological meaning of potential longitudinal time-318 varying genetic effect. 319 320 The changing trends of these 24 phenotypes during pregnancy were largely similar <sup>321</sup>between the two hospitals (**Supplementary Fig. 18-19**). Among the leukocyte-related 322 phenotypes, white blood cell (WBC), neutrophil counts (NEUT), and neutrophil 323 percentages (NEU\_P) increased significantly during pregnancy. In addition, 324 lymphocyte (LYM) levels decreased, monocyte (MON) levels increased, eosinophils <sup>325</sup>(EOS) were essentially unchanged and basophils (BASO) fluctuated at average levels. 326 Red blood cell counts (RBC), hemoglobin (HGB) levels, hematocrit (Hct) and platelet 327 count (PLT) have a significant downward trend during pregnancy. All CBC 328 phenotypes changed greatly in the delivery and postpartum period, tending to return 329 to pre-pregnancy levels. 330 331 We investigated the longitudinal time-varying genetic effect following two steps. First, 332 we applied  $\text{TrajGWAS}^{39}$  to identify genetic variants affecting the phenotypic mean

333 variability across the 24 CBC gestational phenotypes for each hospital, respectively.  $334$  By default, TrajGWAS<sup>39</sup> will also compute the effect of genetic variants affecting the 335 within-subject variability. Genetic variants affecting phenotypic mean and within-336 subject variability ( $\beta_g$  and  $\tau_g$  significant genetic variants) are shown in the <sup>337</sup>**Supplementary Fig. 20-27**. In total, we identified 645 variants associated with the 338 phenotypic mean reaching a genome-wide significance threshold in both hospitals (*P* 339  $\leq 5 \times 10^{-8}$ ). Secondly, we included a genotype dosage and gestational day interaction 340 term in the above TrajGWAS regression model for each hospital, testing the statistical 341 significance of the interaction effect size, similar to a locus-based genetic-by-time 342  $(G \times T)$  analysis (**Methods**). After integrating the two hospital statistics via inverse-343 weighted variance fixed effect meta-analysis, 115 out of 645 the variants (17.8%) 344 demonstrated significant interaction effect with gestational days  $(P < 5 \times 10^{-8})$ <sup>345</sup>(**Supplementary Table 28**), while the rest of the 530 variants only affected the 346 phenotypic mean level but the interaction effects were not significant <sup>347</sup>(**Supplementary Table 29**). Among the 23 phenotypes, the percentage of variants 348 with significant  $G \times T$  effects ranged from 5.4% to 47.8% (**Supplementary Table** <sup>349</sup>**30**). 350 351 To explore how genetic variants specifically change during the first, second, third

352 trimesters of pregnancy, delivery, and postpartum period, we performed localized

<sup>353</sup>association studies of these 115 variants (**Methods, Supplementary Table 31**) and

354 found 79 out of the 115 variants exhibited non-overlapping 95%CIs for genetic effects

<sup>355</sup>in at least two of the five periods (**Supplementary Table 31, Supplementary Fig.** 

<sup>356</sup>**28**). Therefore, we confirm that 79 out of the 645 variants (12.2%) demonstrated

357 substantial and significant changes of genetic effects across the gestation and

358 postpartum period. The 25 variants with the most significant  $G \times T$  interaction effects

359 were demonstrated in Fig. 4A. 22 out of these 25 variants have strong expression

360 quantitative trait loci (eQTL) information (**Supplementary Table 31**). Taking the



- 389 in the genetic effects of variants affecting blood cell levels during pregnancy are more
- 390 related to changes in cell activation and cytokines in pregnant women.
- 391

### <sup>392</sup>**Causal relationship with older-age phenotypes**

<sup>393</sup>To explore whether gestational phenome may influence or correlated with the

394 occurrence of chronic diseases in mothers in the distant future, we first estimated

395 causal effects of the 122 gestational phenotypes on 220 phenotypes examined in the

 $396$  BioBank Japan Study  $(BBJ)^{10}$  using two-sample, inverse variance weighted,

397 bidirectional MR and four additional two-sample approaches as sensitivity analyses.

398 After MR-PRESSO elimination of outliers<sup>40</sup>, 73 significant potential causal

399 relationships were found for the 122 gestational phenotypes, using FDR  $q$ -value less

400 than 0.01 as false discovery rate (FDR) threshold with 1,764 non-collinear phenotypic

401 pairs and excluding Cochran's Q statistic or pleiotropy *P*-value less than 0.05, and

402 these causal relationships were not significant in the reverse MR (Methods). The

<sup>403</sup>bidirectional causal effect estimates were presented in a network view in **Fig. 5A,** 

404 with the forward MR effect estimates of 88 molecular phenotypes presented in Fig.

<sup>405</sup>**5B and Supplementary Table 34** and the forward MR effect estimates of the other

<sup>406</sup>34 phenotypes presented in **Supplementary Fig. 31 and Supplementary Table 35**.

407

<sup>408</sup>We identified numerous previously known and unidentified potential causal

409 associations. Genetically predicated higher gestational BMI contributes to the most of 410 the older-age disorders and phenotypes in our study. It increasing liability of 13 older-411 age disorders or phenotypes with the largest effects observed on chronic renal failure <sup>412</sup>(*OR* [95%CI]: 1.68 [1.42-2.00]), followed by several cardiovascular disorders such as 413 myocardial infarction, peripheral artery disease, chronic heart failure, unstable angina 414 pectoris, type 1 diabetes and cholelithiasis as well as five medication use of drugs and 415 three physical phenotypes, while gestational BMI slightly decreasing liability of two

416 older-age disorders including pneumothorax and pulmonary tuberculosis (**Fig. 5A,** 

#### <sup>417</sup>**Supplementary Fig. 31 and Supplementary Tables 35**).

418



- 420 glycemic biomarkers causally associated with older-age disorders. For example,
- 421 genetically predicted elevated triglyceride levels in pregnant women is associated
- 422 with an increased risk of taking certain medications, such as the medication use of
- 423 antithrombotic agents (*OR* [95%CI]: 1.09 [1.06-1.12],  $P=1.24\times10^{-11}$  (**Fig. 5C,**
- <sup>424</sup>**Supplementary Table 34**). In addition, genetically predicted elevated 1h blood
- 425 glucose levels on the oral glucose tolerance test (OGTT1H) in pregnant women
- <sup>426</sup>increase the risk of peripheral arterial disease (PAD) (*OR* [95%CI]: 1.24 [1.13-1.37],

427  $P=1.24\times10^{-5}$  (**Fig. 5D. Supplementary Table 34**), consistent with prior report of

- 428 glucose abnormalities as a risk factor for  $PAD<sup>41</sup>$ . Moreover, elevated levels of
- <sup>429</sup>genetically predicted OGTT1H also increase the risk of cataract (*OR* [95%CI]: 1.15
- 430 [1.09-1.21],  $P=3.21\times10^{-8}$  (**Supplementary Table 34**), which is in accordance with
- 431 the results of the animal model<sup>42</sup>.
- 432

433 Furthermore, our results also show that genetically increased infections increase

434 certain disease liability. For instance, genetically increased gestational hepatitis B

435 core antibody positive (HBcAb) increases the risk of gastric cancer (*OR* [95%CI]:

436 1.12 [1.06-1.19],  $P=1.06\times10^{-4}$ ), chronic hepatitis B infection (*OR* [95%CI]: 1.31

437 [1.15-1.49],  $P=5.27\times10^{-5}$  and hepatic cancer (*OR* [95%CI]: 1.24 [1.13-1.37],

438  $P=5.02\times10^{-6}$  (**Fig. 5A, Supplementary Table 34**), revealing a potential causal

- 439 relationship between hepatitis B infection observed during pregnancy and
- 440 extrahepatic cancers. Moreover, genetically predicted quantitative levels of
- 441 cytomegalovirus IgG (CMV\_IgG\_quan) were found to be associated with an
- <sup>442</sup>increased risk of some cardiac diseases (angina pectoris: *OR* [95%CI]: 1.31 [1.16-
- 443 1.49],  $P=1.28\times10^{-5}$ ; stable angina pectoris: *OR* [95%CI]: 1.27 [1.16-1.40]; medication

444 use vasodilators used in cardiac diseases: *OR* [95%CI]: 1.26 [1.15-1.38]). This is 445 consistent with previous studies suggesting increased exposure to cytomegalovirus 446 infection is related to coronary artery and vascular atherosclerotic diseases<sup>43,44</sup>. More 447 broadly, we found that genetically predicted increases in BMI during pregnancy were 448 associated with an increased risk of developing a variety of diseases, such as chronic <sup>449</sup>kidney failure (*OR* [95%CI]: 1.68 [1.42-2.00]) and myocardial infarction (*OR* <sup>450</sup>[95%CI]: 1.26 [1.17-1.35]) (**Fig. 5A, Supplementary Table 34, Supplementary Fig.**  <sup>451</sup>**31**). In general, a less superior physiological state during pregnancy is likely to

- 452 threaten the future health of the woman.
- 453

454 The causal impact of the gestational phenotypes (collected from pregnancy women 455 with mean age of 30) may directly contribute to the later-age phenotypes (collected 456 from BBJ with ages ranging from 30 to 70) or the causal effect may be mediated 457 through the same phenotypes in a middle age period. To understand this process, we 458 utilized the previously analyzed IVs with pregnancy-specific and shared effects with 459 the 23 phenotypes shared with the Taiwan Biobank, we added GWAS data from the 460 Taiwan Biobank as a second exposure and conducted a multivariable MR (MVMR). 461 Using FDR *q* value as the threshold of significance (NIPT effect  $q < 0.01$ ), we 462 identified a total of 45 significant causal effects of the gestational phenotypes on the <sup>463</sup>later-age outcomes even after adjusting for the genetic effects of the exposures in the 464 Taiwan Biobank. Among these, 40 effects have a  $q$  value  $> 0.05$  in the Taiwan dataset 465 or having an opposite genetic effect compared to ones with the gestational phenotypes 466 suggesting substantial direct causal effects on the outcomes. The remaining 5 effects 467 have a nominally significant *P* and consistent effect direction in the Taiwan dataset, 468 indicating less strong direct causal effects of the gestational phenotypes on the later <sup>469</sup>age phenotypes (**Supplementary Table 40, Supplementary Fig. 32**). In addition, 470 there are 97 effects having a  $q$  value  $< 0.01$  for the Taiwan while having an opposite 471 beta direction or a  $q$  value  $> 0.05$  in the NIPT dataset, suggesting that the NIPT

472 effects on the outcome is primarily dominated by the middle and older age genetic 473 effects. Among the 40 out of the 143 effects (28.0%) with potential direct causal 474 effects, notable relationships include genetically predicted gestational AFP and 475 AFPMOM in the second trimesters is negatively associated with atopic dermatitis and 476 all types of white blood cell, while it is positively associated with thyroid disorders 477 such as Grave disease, Hashimoto thyroiditis as well as medication use thyroid 478 preparations, chronic sinusitis, Type 2 diabetes and medication use drugs in diabetes <sup>479</sup>(**Supplementary Fig. 32 A-B, Supplementary Table 40**). In addition, genetically 480 predicted albumin during pregnancy is negatively associated with chronic hepatitis B 481 infection and cirrhosis. AST and RBC from NIPT datasets are causally associated 482 with the related blood cell information in the BBJ (**Supplementary Fig. 32 C,** <sup>483</sup>**Supplementary Table 40**). We also compared the results of univariate MR between 484 the 23 gestational phenotypes and the Taiwanese phenotype, and the results have high 485 consistency with an  $\mathbb{R}^2$  of 0.79, consistent with the above statistics where the majority, 486 namely 97 versus 45 of the gestational phenotypic effects on outcomes through older-<sup>487</sup>age phenotypes, and through direct effects (**Supplementary Fig. 33, Supplementary**  <sup>488</sup>**Table 41-42**).

489

#### <sup>490</sup>**Discussion**

491 Our study represents the largest scale GWAS on gestational phenotypes to date and 492 provides the first insight into the dynamic genetic atlas of human gestational 493 phenotypes and their causal associations with older-age health conditions. Using 494 obstetric and NIPT genotype data from 121,579 pregnant women, we identified 3,845 495 genome-wide significant loci, of which 1,385 loci were novel to this study and the 496 majority of which consists of at least one function variant. More than 84.5% of the 497 genetic associations were replicated in independent cohorts. Genes associated with 498 multiple gestational phenotypes are enriched in response to hormones, compound 499 biosynthetic and multi-organism reproductive processes, and PPI network analysis

500 reveals that *IL6* involved in immune responses, *ESR1* related to hormone response 501 and *IGF1* and *EGF* related to cell growth and development are the most essential hub 502 genes, providing the first insights into the role of immune, hormone and cell growth 503 responses and the key gene players in gestational process from a human genetic 504 perspective, beyond previous insights achieved via metabolome of primate pregnancy 5 <sup>505</sup>.

506

507 Notably, the genetic atlas of gestational phenotypes is dynamic, reflecting gestation-508 specific  $G \times E$  and gestation time-varying  $G \times T$  interactions. Combining data from 509 the Taiwan Biobank and using Bayesian classification analysis, we identified 510 pervasive gestation-specific genetic effects that present in around 17.4% of the 511 genetic associations (138/792) with 23 gestational phenotypes, ranging from  $\sim 0\%$  for 512 early pregnancy systolic blood pressure to 100% for alpha-fetoprotein in second 513 trimester. Genes containing gestation-specific genetic effect exhibit a predominant 514 enrichment in pathways involving cancer, response to hormones, lipid, vitamin and 515 glucose metabolisms, and cell growth and development. PPI network analysis 516 highlights *ESR1*, *IGF1* (but not *EGF*) and *IL6* as the most significant hub genes. 517 518 On the other hand, in a longitudinal trajectory GWAS analysis of repeated 519 measurements of 24 complete blood count (CBC) phenotypes, we found significant 520  $G \times T$  interactions present in 12.2% of the genetic variants (79/646) throughout the 521 five gestational, delivery and postpartum periods, with hub genes as *EGF* and *CATA2* 522 in the PPIN, and pathways enriched in regulation of cell growth activity, nerve 523 development and lipid modification. 524 525 Conditions during gestational period were deems as unique opportunities for early 526 screening and prediction for late-onset chronic disease risk in women<sup>45</sup>. Our results 527 suggest causal relationships between adverse gestational conditions and

528 cardiovascular disease, including obesity, dyslipidemia and dysglycemia. We also 529 found that genetically predicted blood glucose abnormalities during pregnancy were 530 associated with an increased risk of cataracts. Previous study has shown that pregnant 531 women with gestational diabetes mellitus, even if they do not have type 2 diabetes, 532 have an increased risk of developing cataracts<sup>46</sup>. In addition, multivariable Mendelian 533 randomization results indicate that high AFP levels during pregnancy are likely to 534 lead to inflammation-related diseases and diabetes, adjusted for mid-life health status. 535 Thus, the state of pregnancy is related to women's health in the long term. 536 537 There are some limitations which are connected to future perspectives in our study. 538 First, although the current study represents the largest GWAS for the majority of the 539 phenotype, the current study participants are restricted to East-Asian participants, and 540 the genetic novel discoveries may be different among non-East-Asian population. 541 However, the study methods made available in this study provides a foundation for 542 expanding the participants from non-East-Asian ancestry, which is promising as NIPT

543 tests as well as pregnancy screening programs are undertaken globally around the 544 world. The future comparisons of European and East-Asian gestational phenotypes 545 may lead to new insights into the ethnic difference for gestational phenotypes and its 546 relationship to offspring's health<sup>47</sup>. In addition, the cross-ancestral analysis will 547 facilitate fine-mapping and validation of the functional variants identified in this study. 548 Secondly, while we provide a dynamic view of the genetic atlas of the gestational 549 phenotypes based on a robust statistical framework, unravelling 12 to 17% of 550 gestation-specific genetic effects and time-varying genetic effects, unravelling novel 551 genes involved in immune and hormone response, and cell-growth and development 552 in determining phenotypic distribution specifically during gestation. How these genes 553 may influence and modulate how gestation initializes and progresses, and how they 554 might contribute to abnormal gestations requires further comparisons or investigations 555 in the patient-oriented study and more in-depth mechanistic study conditioning on the

556 findings in this study. Thirdly, beyond the genetic and causal relationships between 557 gestational phenotypes and broad human complex and older age phenotypes 558 investigated in our study, another important investigation will be the dissection of 559 fetal genetic and intrauterine effects on birth outcomes and offspring health 560 conditioning on the dynamic atlas presented here and expanding birth cohort genome 561 studies $14$ . 562 563 The genetic discoveries in this study provides foundational insights into the dynamics 564 of genetic landscape of the human gestational period. As we continue to expand the

565 genomic data and methods, future efforts will be prioritized to combine the genetic

566 information to dissect the developmental origin of children and adult disorders and for

567 exploring health and risk prediction for women during the gestational time window.

568 These should be conducted in global efforts.

569

570

## <sup>571</sup>**Methods**

#### <sup>572</sup>**Study population**

573 From 2017 to 2022, we recruited 121,579 pregnant women who performed maternity 574 checkups in Shenzhen Baoan Women's and Children's Hospital and Longgang District 575 Maternity and Child Healthcare Hospital of Shenzhen City into our study. Pregnant 576 women received prenatal and postnatal serum biomarkers testing and non-invasive 577 prenatal testing (NIPT) in the first or second trimester or both of pregnancy. Maternal 578 genotypes were inferred from low-depth whole-genome sequencing data generated  $579$  from NIPT using our previously developed advanced methods<sup>7</sup>. In addition, we also 580 collected basic physical measurements of participants and their babies' birth outcomes. 581 The details of the number of participants in each test are presented in Supplementary <sup>582</sup>Table (**Supplementary Table 2-3**). The age distribution of pregnant women and the

583 prevalence of some gestational comorbidities in the two hospitals are shown in the 584 supplementary material (**Supplementary Table 4-5, Supplementary Fig. 1-2**).

585

<sup>586</sup>We integrated all the obstetrical data, including genotypic and phenotypic data, to 587 explore the genetic and molecular risk factors underlying the phenotypic spectrum of 588 pregnant biomarkers. This study was approved by the Medical Ethics Committee of 589 the School of Public Health (Shenzhen), Sun Yat-sen University, Longgang District 590 Maternity and Child Healthcare Hospital of Shenzhen City, and Shenzhen Baoan 591 Women's and Children's Hospital. Data collection was approved by the Human 592 Genetic Resources Administration of China (HGRAC).

593

#### <sup>594</sup>**Phenotype definition**

595 In the genome-wide association study (GWAS) analyzing gestational phenotypes, we 596 collected 122 maternal phenotypes in nine categories concerning Blood lipid  $(N=2)$ , 597 Glycemic (N=6), Blood routine (N=32), Infection (N=14), Kidney function (N=3), 598 Liver function (N=8), Thyroid function (N=4), Tang screening (N=16) and NIPT 599 screening (N=3), as well as three categories including Basic information (N=7), <sup>600</sup>Gestational disorders (N=21) and Birth outcomes (N=6) (**Supplementary Table 2-3**). 601 For phenotypes with multiple measurements, we filtered out the record with the 602 earliest measurement date. In longitudinal genetic analyses, we retained all 603 measurements of complete blood count (CBC).

604

# <sup>605</sup>**Genotype imputation from Non-Invasive Prenatal Testing data and**  <sup>606</sup>**quality control**

607 NIPT for fetal trisomy by sequencing maternal plasma free DNA (cfDNA) is new 608 genomic sequencing technology<sup>48</sup>. Large-scale low-pass and mediate-coverage 609 sequencing data are available through NIPT. In our previous study, we demonstrated 610 that NIPT data can be used effectively for GWAS analysis<sup>7</sup>. Therefore, it is robust that

611 we use imputed NIPT data for genetic basis of prenatal and postnatal screening 612 indicators.

613

614 Genotype imputation from NIPT data was conducted by genotype likelihoods 615 imputation and phasing method using GLIMPSE software (version  $1.1.1$ )<sup>49</sup> with 616 10,000 Chinese population high-depth sequencing genotype as reference panel<sup>50</sup>. Loci 617 with minor allele frequency less than 0.001 were filtered in advance for reference 618 panel. To address confounding by population relatives, we excluded the duplicated 619 sequencing records of the same people from different pregnant times and kept the 620 highest sequencing depth.

621

### <sup>622</sup>**Family relatedness and principal component analyses**

623 PLINK<sup>51</sup> (version 2.0) was used to select SNPs with an MAF of at least 5%. The 624 kinship was calculated based on the KING-robust kinship estimator. We used a cutoff 625 of approximately 0.354 to identified monozygotic twins and duplicate samples. In 626 addition, we applied PLINK<sup>51</sup> (version 2.0) for principal component analyses (PCA) 627 both before and after genotype imputation.  $EMU<sup>52</sup>$  (version 0.9) was used for PCA 628 specifically before genotype imputation.

629

#### <sup>630</sup>**Variant annotation**

631 We performed variant annotation using Ensembl Variant Effect Predictor (VEP) 632 (version 101)<sup>53</sup>, with indexed GRCh38 cache files (version 109). HGVS notations <sup>633</sup>were generated by primary assembled reference FASTA files for *Homo sapiens*. All 634 these data for annotation were pre-downloaded from the Ensembl FTP server 635 (https://ftp.ensembl.org/pub/). Since a variant may overlap with multiple transcripts, 636 we used the --pick option to assign one block of results to each variant based on a set 637 of VEP default criteria. For variants located in intergenic regions, we used the --

638 nearest option to identify the nearest gene to the protein-coding transcription start site

639 (TSS).

640

#### <sup>641</sup>**Genome-wide association analysis and conditional analysis**

642 After quality control of the sequencing data and imputation of genotype from the 643 NIPT data, we conducted genome-wide association analysis using  $PLINK^{51}$  (version <sup>644</sup>2.0) to examine the association of the 122 phenotypes, assuming additive genotype 645 effects. For quantitative traits, we utilized linear regression model for GWAS, and for 646 qualitative traits, we used logistic regression model. To account for population 647 stratification, we considered some or all the following as covariates in the GWAS for 648 all phenotypes: maternal age, body mass index (BMI), gestational week at the time of 649 indicators measurement, and the top ten principal components. All GWAS covariates <sup>650</sup>were shown in the **Supplementary Table 6**.

651

652 Using the GWAS summary statistics from two hospitals, we performed meta-analyses 653 using METAL<sup>54</sup> (version 2011-03-25) with an inverse-variance weighted (IVW) 654 fixed-effect model. To visualize the meta-analyses results, we generated fuji plot 655 using R script and Circos software<sup>55,56</sup>. Then, we used the GWAS meta summary 656 statistics for all the subsequent analyses.

657

658 To identify independent genome-wide significant signals  $(P < 5 \times 10^{-8})$ , we used 659 GCTA<sup>57</sup> multi-SNP-based conditional & joint association analysis (COJO<sup>18</sup>) with a 660 stepwise model selection (--cojo-slct). Variants with MAF  $< 0.01$  were filtered and 661 the colinearity threshold was 0.2. 500kb upstream and downstream block of a 662 genome-wide significant signal was divided into a separate locus. The SNP with the 663 smallest *P* value in each locus was selected as the lead SNP. In addition, if the SNP 664 had *P* value less than  $4.1 \times 10^{-10}$ , it was considered to be a variant that reached the 665 study-wide significance. Similarly, we used the same method to select independent

666 SNPs from the 220 GWAS summary statistics of BBJ cohort<sup>10</sup> and 23 GWAS 667 summary statistics of Taiwan Biobank<sup>19</sup> for subsequent analysis.

668

### <sup>669</sup>**Replication of independent genome-wide significant signals**

670 To examine whether genetic effects of the same phenotype were equivalent between 671 the two cohorts, we performed internal replication and external comparison of 672 independent genome-wide significant SNPs obtained from conditional analysis using 673 two methods. In the internal replication, we compared the direction of beta and *P* 674 value of each SNP in the two hospitals. The criteria for a SNP to be replicated were 675 that it had consistent beta direction and the *P* value was less than the Bonferroni-676 corrected significant threshold (0.05/number of independent SNPs per phenotype). In 677 the second approach, based on the central limit theorem, we utilized a *two-sample t-*<sup>678</sup>*test* with the following hypotheses:

**Nutter** hypothesis  $H_0: p_1 - p_2$ 

Alternative hypothesis  $H_1$ :  $p_1 + p_2$ 

679 The statistic  $T$  was calculated as follows:

$$
T = \frac{\beta_1 - \beta_2}{\sqrt{SE_1^2 + SE_2^2}} \sim t(v') \tag{1}
$$

680 The degrees of freedom  $v'$  were calculated by the formula:

$$
v' = \frac{(SE_1^2 + SE_2^2)^2}{SE_1^4 + \frac{SE_2^4}{n_2 - 1}} \tag{2}
$$

681 In the formulas,  $\beta$  represents the estimate of the genetic effect, *SE* represents the 682 standard error of the genetic effect estimate, and *N* represents the sample size of trait 683 int the cohort. The  $P$  value was calculated using the statistic  $T$  and degrees of freedom  $684$  *v'* obtained from the formulas, and the SNP was replicated successfully if the *P* value 685 was greater than 0.05. In addition, we used METAL to estimate heterogeneity tests for 686 the genetic effects of SNPs between the two hospitals, and *P* value  $\geq$ 0.05 were taken

687 to indicate that there was no heterogeneity in the genetic effects of the SNP between 688 the two hospitals.

689

<sup>690</sup>We conducted external replication of the identified variants using the NIPT PLUS 691 pregnancy cohort, which is a data collection of 5,733 individuals who sought maternal 692 check-ups at Shenzhen Baoan Women's and Children's Hospital (Shenzhen, China) 693 throughout the entire 40-week gestational period. Between 2020 and 2021, these 694 pregnant women received NIPT in the first or second trimester and provided written 695 informed consent. Besides, these samples were sequenced at a deeper depth compared 696 to traditional NIPT. The genotyping and quality control process of NIPT PLUS cohort 697 participants were the same as Baoan and Longgang. Among the 122 phenotypes in 698 this study, 103 phenotypes could be replicated in the NIPT PLUS pregnancy cohort. <sup>699</sup>We used the same methods as for the internal replication to perform external 700 replication of the variants for these 103 phenotypes.

701

# <sup>702</sup>**Comparison of genetic effects on maternal height and Taiwanese**  <sup>703</sup>**population height**

<sup>704</sup>As maternal height is essentially unchanged during pregnancy, we demonstrate the 705 effectiveness of our GWAS results by comparing the genetic effects of height in the 706 Taiwanese population with the genetic effects of maternal height related variants<sup>19</sup>. 707 We extracted genome-wide significant independent variants associated with height in 708 Taiwanese population and found corresponding genetic effects in our GWAS 709 summary statistic. Comparisons were made using the Bonferroni correction threshold 710 method and the rate of success in the comparison was calculated.

711

#### <sup>712</sup>**Identification of novel locus and signal**

713 We downloaded all associations (v1.0.2 e109 r2023-02-15) from GWAS Catalog<sup>20</sup>

714 to identify novel associated SNPs. A trait associated locus was considered novel when

715 the  $\pm$ 500kb range of the lead SNP did not include previously reported associations in 716 the GWAS Catalog for the same trait. In addition, we considered a trait-associated 717 signal as novel when it satisfied that the  $R^2$  between the GWAS Catalog reported 718 SNPs and our SNP was less than 0.2. The  $R^2$  calculations were performed on the 719 LDpair Tool through LDlink<sup>58</sup> (version 5.5.1) based on GRCh38 1000G genome build 720 in the EAS and EUR populations.

721

#### <sup>722</sup>**Protein-protein interaction network analysis**

723 We selected genes hosting loci in our study for protein-protein interaction (PPI)

724 analysis. Genes with PPI score  $> 0.4$  were chosen to build a network model visualized

- 725 by Cytoscape (Version:3.10.1)<sup>59</sup>. The degree algorithm implemented in CytoHubba<sup>60</sup>
- 726 was used to compute the top 10 hub genes. Software parameters used default

727 parameters.

728

### <sup>729</sup>**Genetic heritability and correlation estimates**

<sup>730</sup>We standardized the phenotypic data and calculated their Spearman correlation 731 coefficients to obtain the phenotypic correlation matrix. Then the meta GWAS 732 summary statistics were used to estimate SNP-based heritability and genetic 733 correlation  $(r_g)$  for all phenotypes using LD Score Regression<sup>33,61</sup>. GCTA<sup>62</sup> was used 734 to calculate LD score files using 10,000 Chinese population high-depth sequencing 735 genotype. The genome was chopped into segments with length of 1000kb (--ld-wind 736 1000), and the cutoff for LD  $R^2$  was 0.01 (--ld-rsq-cutoff 0.01). The phenotypic 737 correlation matrix and genetic association matrix of the two hospitals were extracted 738 to draw heat maps, respectively.

739

#### <sup>740</sup>**Detection of pregnancy-specific effects**

741 Because of the paucity of currently available GWAS summary statistics for pregnancy 742 and the influence of population structure, we used GWAS summary statistics for

743 similar phenotypes from the Taiwan Biobank<sup>19</sup>, which were downloaded for external 744 comparisons. Three conditions were required for an independent SNP to be compared: <sup>745</sup>1) the SNP was present in the externally compared GWAS summary statistic; 2) the 746 effect allele and the direction of the genetic effect were the same as those of the 747 externally data; and 3) the *P* value was less than the Bonferroni-corrected threshold 748 (0.05/number of loci).

749

750 We applied linemodels package<sup>36</sup>  $(\frac{https://github.com/mipirinen/linemodels}{https://github.com/mipirinen/linemodels})$  to the 751 GWAS summary statistics from gestational phenotypes GWAS and similar 752 phenotypes GWAS in the general population of East Asia. The analysis included <sup>753</sup>1,318 variants in 23 phenotypes (**Supplementary Table 23**). We classified the 754 variants into two clusters based on their effect sizes, pregnancy specific variants and 755 general variants. If the genetic effect of the variant is more different from that of the 756 general population in East Asia, it is called a pregnancy specific variant (posterior 757 probability of pregnancy  $> 0.95$ ), and if the genetic effect is more consistent between 758 the two, it is called a general variant (posterior probability of general  $> 0.95$ ). The 759 clusters were represented by line models where the slope of the pregnancy cluster is 760 fixed to 0, the correlations are fixed to 0.999 in both clusters, and the other parameters 761 are estimated using EM algorithm. The parameters of the various categories are 762 shown in **Supplementary Table 23**. The slope represents the slopes of the two lines, 763 and the scale determines the magnitude of effect sizes, and the correlation determines 764 the allowed deviation from the lines.

765

766 To exclude the effect of LD structure on classification, we performed colocalization 767 analyses of variants in gestational phenotypes and variants in East Asian populations 768 with the same or similar phenotypes and adjusted the linemodes results depending on 769 colocalization results. We set the prior probability of an SNP associated with 770 phenotypes of pregnant women  $(p_1)$  and in East Asia  $(p_2)$  as  $1\times10^{-4}$ , and the prior

771 probability of an SNP associated with both traits  $(p_{12})$  as  $5\times10^{-6}$  63. We adjusted the 772 classification results by adopting the following criteria. If a variant classified as a 773 pregnancy cluster in line models had a posterior probability (PPH4)  $< 0.2$ , the 774 classification result remained unchanged; otherwise, it was classified as an uncertain 775 cluster; if a variant in a general cluster had a PPH4  $> 0.8$ , the classification result 776 remained unchanged; otherwise, it was classified as an uncertain cluster; if a variant 777 classified as a uncertain cluster in line models had a PPH4  $< 0.2$ , it was classified as 778 an pregnancy cluster; if a variant classified as a uncertain cluster in line models had a 779 PPH4  $> 0.8$ , it was classified as an general cluster. The results of the classification of 780 the other cases are consistent with line models.

781

#### <sup>782</sup>**Enrichment analysis of variants**

783 Based on the results of line models, we performed enrichment analysis using 784 Metascape  $(v3.5.20240101)^{64}$ . This method calculates the hit rate with our gene list 785 and the background hit rate based on the number of genes in each section, and the 786 ratio of the two is the enrichment factor. The *P*-value is defined as the probability of 787 obtaining multiple pathways, forming a cumulative hypergeometric distribution, the 788 more negative the value, the less likely it is that the observed enrichment is due to 789 randomness. The analysis was performed with default parameters, namely, the min 790 overlap was set to 3, the  $P$  value cutoff was 0.01, the min enrichment factor was 1.5. 791 Ontology category included GO Biological Processes, Reactome Gene Sets, KEGG 792 Pathway, WikiPathways, Canonical Pathways and PANTHER Pathway.

793

<sup>794</sup>We performed separate enrichment analyses for genes with pregnancy-specific 795 variants and genes with general variants, selecting the top 20 pathways with the most 796 significant pregnancy-specific variants and comparing them with the general variants. <sup>797</sup>We also aggregated all genes for enrichment analysis of single gene lists.

798

#### <sup>799</sup>**Longitudinal trajectories of genetic effects**

800 We conducted analyses using  $\text{TrajGWAS}^{39}$  to identify genetic variants that contribute 801 to change in gestational phenotypes during pregnancy and postpartum. We used 802 gestational day as a time factor to determine whether there was a genetic-time 803 interaction. GWAS for longitudinal biomarkers was performed using the TrajGWAS 804 method, based on a mixed effects model with the following formula:

$$
y_{ij} = x_{ij}\beta + g_i\beta_g + G \times T \times \beta_{G\times T} + \varepsilon_{ij}
$$
 (3)

805  $y_{ij}$  represents the phenotypic value of the jth measurement for the ith pregnant 806 woman.  $x_{ij}$  represents fixed-effects covariates, including the first ten principal 807 components, maternal age and gestational days at phenotypic testing,  $\beta$  is its 808 corresponding effect value.  $g_i$  denotes the genotype dosage for the ith pregnant 809 woman, corresponding to a genetic effect of  $\beta_g$ .  $G \times T$  represents the interaction 810 between maternal genotype dosage and gestational time, corresponding to an effect 811 value of  $\beta_{G \times T}$ .  $\varepsilon_{ij}$  is a random-effects term reflecting the variance of the genetic 812 variants affecting the within-subject (WS) variance of the biomarker. The formula for 813 the variance  $\sigma_{\varepsilon_{ij}}^2$  of  $\varepsilon_{ij}$  is given below:

$$
\sigma_{\varepsilon_{ij}}^2 = \exp \left( \tau w_{ij} + \tau_g g_i + \tau_{G \times T} G \times T + \omega_i \right) (4)
$$

814  $w_{ij}$  is a covariate including the first 10 principal components, maternal age, and 815 gestational days at phenotypic measurement, and  $\tau$  is the corresponding effect value. 816  $\tau_g$  denotes the genetic effect affecting the variance of WS.  $\tau_{GXT}$  indicates the effect 817 value for the interaction of maternal genotype dosage and gestational time.  $\omega_i$  denotes 818 the random intercept.

819

820 There were 24 of these phenotypes, involving phenotypes of the Blood routine 821 categories (N=24). Specific phenotypes are shown in **Supplementary Table 27**. 822 Following the procedure described by Ko et al., we first performed the score test for 823 SNPs, obtaining the direction of the effect ( $\beta_g$  or  $\tau_g$ ) and the *P* value that affected the 824 mean and within-subject variability for each phenotype. Subsequently, the Wald test

825 was performed on SNPs with a *P* value of  $\beta_g$  or  $\tau_g$  less than  $5 \times 10^{-8}$  to estimate the 826 effect sizes of the genetic effect of genotype dosage ( $\beta_g$  or  $\tau_g$ ) and the effect of 827 interaction between maternal genotype dosage and gestational time ( $\beta_{G \times T}$  or  $\tau_{G \times T}$ ). 828 Subsequently, we performed a meta-analysis of the effect values of these significant 829. SNPs using METAL<sup>54</sup>. TrajGWAS analyses were performed with the Julia package 830 TrajGWAS.jl (https://github.com/OpenMendel/TrajGWAS.jl)<sup>65</sup>. Manhattan and QQ 831 plots in the supplementary figures were drawn with a Julia package MendelPlots.jl 832 (https://github.com/OpenMendel/MendelPlots.jl)<sup>65</sup> with SNP minor allele 833 frequency $>0.01$ . To identify independent significant loci, we used a python script 834 where the variant with the smallest *P* value in the 1Mb range was the lead SNP, and 835 variants within 500kb above and below the lead variant were classified into a locus. 836

837 In order to investigate whether the genetic effects of the loci identified by TrajGWAS 838 change during a total of five periods: first, second, and third trimester of pregnancy, 839 day of delivery, and within 42 days postpartum, we performed localized association 840 analyses of these loci. The main steps were consistent with the previous GWAS, 841 except that the PLINK<sup>51</sup> (version 2.0) parameters --chr, --from-bp, and --to-bp were 842 used to point to the loci. We defined a variant with change as a non-overlapping 95% 843 confidence interval (CI) for the genetic effect in at least two of the five periods.

844

845 We enriched the variants with significant genotype dosage for significant and non-846 significant interactions between genetics and environment. Methods were the same as 847 for the enrichment analyses described above.

848

# <sup>849</sup>**Mendelian randomization network of pregnancy, Taiwanese and**  <sup>850</sup>**BBJ traits**

851 To identify whether pregnancy status affects the development of future disease 852 progression, bidirectional mendelian randomization analyses were performed on

853 cohort of this study and Japanese Biobank cohort data with the TwoSampleMR 854 package<sup>66,67</sup>. We used GWAS summary statistics from two cohorts and independent 855 SNPs obtained from GCTA-COJO as genetic instruments ( $P < 5 \times 10^{-8}$ ) in our MR 856 analyses. We also calculated the proportion of variance in phenotypes explained (PVE) 857 by the instruments according to the formula<sup>68</sup> (3) and calculated the F-statistic 858 according to formula (4) to evaluate the strength of instruments, with  $F$  values greater 859 than 10 indicating sufficient strength.

$$
PVE = \frac{2\hat{\beta}^2 MAF (1 - MAF)}{2\hat{\beta}^2 MAF (1 - MAF) + \left( se(\hat{\beta}) \right)^2 2NMAF (1 - MAF)}
$$
(5)  

$$
F = \frac{N - nsnp - 1}{nsnp} \times \frac{PVE}{1 - PVE}
$$
(6)

860 The assessments of the instrumental variables are shown in the **Supplementary** <sup>861</sup>**Table 36-39**. We conducted sensitivity analyses using alternative MR methods that 862 including: 1) MR Egger; 2) Simple mode; 3) Weighted median; 4) Weighted mode. 863 Among the several methods of MR analyses, the inverse variance weight (IVW) 864 method which confers the greatest statistical power for estimating causal associations 865 was used as primary reference<sup>69</sup>.

866

867 To examine and address horizontal pleiotropy in causal relationships inferred from 868 MR analyses, we performed MR-PRESSO<sup>40</sup> using the results of the first two-sample 869 MR. The outliers were found using MR-PRESSO and tested for differences between 870 the pre-correction and post-correction results. The outliers would be excluded, and the 871 two-sample MR was performed again if the difference was significant.

872

873 Robust causal estimates were defined as those that were significant at FDR *q* value of 874 IVW<sup>70</sup> ( $q$  < 0.01) and showed no evidence of heterogeneity ( $P > 0.05$ ) and horizontal 875 pleiotropy ( $P > 0.05$ ) after MR-PRESSO.

876

877 We also performed two-sample MR of 23 Taiwanese phenotypes with 220 BBJ 878 phenotypes. The methodology is the same as in the previous section. Genetic 879 instrumental variable information is displayed in **Supplementary Table 43-44**.

880

881 To adjust for the influence of mid-life health status on causal relationships, we 882 incorporated 23 phenotypes from the Taiwan Biobank<sup>19</sup> as a second exposure in the 883 multivariable mendelian randomization analysis<sup>71,72</sup>. The gestational phenotype and 884 the Taiwan Biobank phenotype were used as exposures, and the 220 phenotypes from 885 the BBJ were used as outcomes. We also used the TwoSampleMR package. The 886 significance threshold is  $q < 0.01$ .

887

888

889<br>890

000<br>001

00 1<br>888

002<br>888

099<br>1

# **Reference**



- 921 11. Graham, S.E. et al. The power of genetic diversity in genome-wide association <sup>922</sup>studies of lipids. *Nature* **<sup>600</sup>**, 675-679 (2021).
- 923 12. Elliott, A. *et al.* Distinct and shared genetic architectures of gestational
- 924 diabetes mellitus and type 2 diabetes. *Nat Genet* **56**, 377-382 (2024).
- 925 13. Juliusdottir, T. et al. Distinction between the effects of parental and fetal 926 genomes on fetal growth. *Nat Genet* **53**, 1135-1142 (2021).
- 927 14. Huang, S. *et al.* The Born in Guangzhou Cohort Study enables generational 928 genetic discoveries. *Nature* **626**, 565-573 (2024).
- 929 15. Mitha, A. et al. Neurological development in children born moderately or late 930 preterm: national cohort study. *Bmj* **384**, e075630 (2024).
- 931 16. Crump, C. *et al.* Adverse pregnancy outcomes and long term risk of ischemic <sup>932</sup>heart disease in mothers: national cohort and co-sibling study. *Bmj* **<sup>380</sup>**,
- 933 e072112 (2023).
- 934 17. Liu, S. et al. Utilizing Non-Invasive Prenatal Test Sequencing Data Resource 935 for Human Genetic Investigation. *bioRxiv*, 2023.12. 11.570976 (2023).
- 936 18. Yang, J. *et al.* Conditional and joint multiple-SNP analysis of GWAS
- 937 summary statistics identifies additional variants influencing complex traits. <sup>938</sup>*Nat Genet* **<sup>44</sup>**, 369-75, s1-3 (2012).
- 939 19. Chen, C.Y. et al. Analysis across Taiwan Biobank, Biobank Japan, and UK

940 Biobank identifies hundreds of novel loci for 36 quantitative traits. *Cell* <sup>941</sup>*Genom* **<sup>3</sup>**, 100436 (2023).

- 942 20. Sollis, E. et al. The NHGRI-EBI GWAS Catalog: knowledgebase and <sup>943</sup>deposition resource. *Nucleic Acids Res* **<sup>51</sup>**, D977-d985 (2023).
- 944 21. Kelleher, A.M., DeMayo, F.J. & Spencer, T.E. Uterine Glands:
- 945 Developmental Biology and Functional Roles in Pregnancy. *Endocr Rev* 40, 946 1424-1445 (2019).
- <sup>947</sup>22. Mills, M.C. *et al.* Identification of 371 genetic variants for age at first sex and <sup>948</sup>birth linked to externalising behaviour. *Nat Hum Behav* **<sup>5</sup>**, 1717-1730 (2021).

- 949 23. Gibson, D.A. *et al.* Profiling the expression and function of oestrogen receptor
- 950 isoform ER46 in human endometrial tissues and uterine natural killer cells.
- <sup>951</sup>*Hum Reprod* **<sup>35</sup>**, 641-651 (2020).
- 952 24. Schlaikjær Hartwig, T. et al. Cell-free fetal DNA for genetic evaluation in
- 953 Copenhagen Pregnancy Loss Study (COPL): a prospective cohort study.
- <sup>954</sup>*Lancet* **<sup>401</sup>**, 762-771 (2023).
- <sup>955</sup>25. Chitty, L.S. Use of cell-free DNA to screen for Down's syndrome. *N Engl J*  <sup>956</sup>*Med* **<sup>372</sup>**, 1666-7 (2015).
- 957 26. Wang, W. et al. Homozygous variants in PANX1 cause human oocyte death 958 and female infertility. *Eur J Hum Genet* 29, 1396-1404 (2021).
- <sup>959</sup>27. Sang, Q. *et al.* A pannexin 1 channelopathy causes human oocyte death. *Sci*  <sup>960</sup>*Transl Med* **<sup>11</sup>**(2019).
- <sup>961</sup>28. Brinkmann, V. *et al.* Neutrophil extracellular traps kill bacteria. *Science* **<sup>303</sup>**, 962 1532-5 (2004).
- 963 29. Bouvier, S. et al. NETosis Markers in Pregnancy: Effects Differ According to <sup>964</sup>Histone Subtypes. *Thromb Haemost* **<sup>121</sup>**, 877-890 (2021).
- 965 30. Guillotin, F. et al. Vital NETosis vs. suicidal NETosis during normal 966 pregnancy and preeclampsia. *Front Cell Dev Biol* **10**, 1099038 (2022).
- 967 31. Yu, G. et al. APRIL and TALL-I and receptors BCMA and TACI: system for 968 regulating humoral immunity. *Nat Immunol* **1**, 252-6 (2000).
- 969 32. Duan, T. *et al.* USP3 plays a critical role in the induction of innate immune 970 tolerance. *EMBO Rep* 24, e57828 (2023).
- <sup>971</sup>33. Bulik-Sullivan, B.K. *et al.* LD Score regression distinguishes confounding 972 from polygenicity in genome-wide association studies. *Nat Genet* **47**, 291-5 973 (2015).
- 974 34. lab, N. UK Biobank-Neale lab. (2018).
- <sup>975</sup>35. Dalmia, A. *et al.* A genetic epidemiological study in British adults and older 976 adults shows a high heritability of the combined indicator of vitamin  $B(12)$





- 1007 46. Auger, N., Tang, T., Healy-Profitós, J. & Paradis, G. Gestational diabetes and 1008 the long-term risk of cataract surgery: A longitudinal cohort study. *J Diabetes* <sup>1009</sup>*Complications* **<sup>31</sup>**, 1565-1570 (2017).
- 1010 47. Patel, R.R., Steer, P., Doyle, P., Little, M.P. & Elliott, P. Does gestation vary
- 1011 by ethnic group? A London-based study of over 122,000 pregnancies with
- 1012 spontaneous onset of labour. *Int J Epidemiol* 33, 107-13 (2004).
- 1013 48. Cheung, S.W., Patel, A. & Leung, T.Y. Accurate description of DNA-based <sup>1014</sup>noninvasive prenatal screening. *N Engl J Med* **<sup>372</sup>**, 1675-7 (2015).
- 1015 49. Rubinacci, S., Ribeiro, D.M., Hofmeister, R.J. & Delaneau, O. Efficient
- 1016 bhasing and imputation of low-coverage sequencing data using large reference <sup>1017</sup>panels. *Nature Genetics* **<sup>53</sup>**, 120-126 (2021).
- 1018 50. Cheng, S. et al. The STROMICS genome study: deep whole-genome
- 1019 sequencing and analysis of 10K Chinese patients with ischemic stroke reveal

1020 complex genetic and phenotypic interplay. *Cell Discov* **9**, 75 (2023).

- 1021 51. Chang, C.C. *et al.* Second-generation PLINK: rising to the challenge of larger <sup>1022</sup>and richer datasets. *Gigascience* **<sup>4</sup>**, 7 (2015).
- 1023 52. Meisner, J., Liu, S., Huang, M. & Albrechtsen, A. Large-scale inference of
- 1024 population structure in presence of missingness using PCA. *Bioinformatics* 37, 1025 1868-1875 (2021).
- <sup>1026</sup>53. McLaren, W. *et al.* The Ensembl Variant Effect Predictor. *Genome Biol* **<sup>17</sup>**, 1027 122 (2016).
- 1028 54. Willer, C.J., Li, Y. & Abecasis, G.R. METAL: fast and efficient meta-analysis 1029 of genomewide association scans. *Bioinformatics* **26**, 2190-2191 (2010).
- 1030 55. Krzywinski, M. et al. Circos: an information aesthetic for comparative

<sup>1031</sup>genomics. *Genome Res* **<sup>19</sup>**, 1639-45 (2009).



- <sup>1033</sup>population links cell types to complex human diseases. *Nat Genet* **<sup>50</sup>**, 390-400 1034 (2018).
- 1035 57. Yang, J., Lee, S.H., Goddard, M.E. & Visscher, P.M. GCTA: A Tool for
- 1036 Genome-wide Complex Trait Analysis. *The American Journal of Human*
- <sup>1037</sup>*Genetics* **<sup>88</sup>**, 76-82 (2011).
- 1038 58. Machiela, M.J. & Chanock, S.J. LDlink: a web-based application for exploring 1039 population-specific haplotype structure and linking correlated alleles of
- 1040 possible functional variants. *Bioinformatics* **31**, 3555-7 (2015).
- 1041 59. Shannon, P. *et al.* Cytoscape: a software environment for integrated models of <sup>1042</sup>biomolecular interaction networks. *Genome Res* **<sup>13</sup>**, 2498-504 (2003).
- <sup>1043</sup>60. Chin, C.-H. *et al.* cytoHubba: identifying hub objects and sub-networks from 1044 complex interactome. *BMC Systems Biology* 8, S11 (2014).
- <sup>1045</sup>61. Bulik-Sullivan, B. *et al.* An atlas of genetic correlations across human diseases <sup>1046</sup>and traits. *Nat Genet* **<sup>47</sup>**, 1236-41 (2015).
- <sup>1047</sup>62. Yang, J. *et al.* Genetic variance estimation with imputed variants finds
- <sup>1048</sup>negligible missing heritability for human height and body mass index. *Nat*  <sup>1049</sup>*Genet* **<sup>47</sup>**, 1114-20 (2015).
- <sup>1050</sup>63. Wallace, C. Eliciting priors and relaxing the single causal variant assumption <sup>1051</sup>in colocalisation analyses. *PLoS Genet* **<sup>16</sup>**, e1008720 (2020).
- <sup>1052</sup>64. Zhou, Y. *et al.* Metascape provides a biologist-oriented resource for the
- <sup>1053</sup>analysis of systems-level datasets. *Nat Commun* **<sup>10</sup>**, 1523 (2019).
- 1054 65. Zhou, H. *et al.* OPENMENDEL: a cooperative programming project for <sup>1055</sup>statistical genetics. *Hum Genet* **<sup>139</sup>**, 61-71 (2020).
- <sup>1056</sup>66. Hemani, G. *et al.* The MR-Base platform supports systematic causal inference 1057 across the human phenome. *eLife* **7**(2018).

- 1058 67. Li, J., Hemani, G., Tilling, K. & Davey Smith, G. Orienting the causal
- 1059 relationship between imprecisely measured traits using GWAS summary data.
- <sup>1060</sup>*PLOS Genetics* **<sup>13</sup>**(2017).
- 1061 68. Teslovich, T.M. *et al.* Biological, clinical and population relevance of 95 loci 1062 for blood lipids. *Nature* **466**, 707-13 (2010).
- 1063 69. Slob, E.A.W. & Burgess, S. A comparison of robust Mendelian randomization
- <sup>1064</sup>methods using summary data. *Genetic Epidemiology* **<sup>44</sup>**, 313-329 (2020).
- 1065 70. John D. Storey, A.J.B., Alan Dabney, David Robinson. qvalue: Q-value
- 1066 estimation for false discovery rate control. R package version 2.36.0 (2024).
- <sup>1067</sup>71. Sanderson, E. Multivariable Mendelian Randomization and Mediation. *Cold*  <sup>1068</sup>*Spring Harb Perspect Med* **<sup>11</sup>**(2021).
- 1069 72. Vabistsevits, M. Setting up Multivariable Mendelian Randomization analysis 1070 in R. (22 March, 2021).
- 1071
- 1072

# <sup>1073</sup>**Figure Legends**

## <sup>1074</sup>**Figure 1. Schematic overview of the study.**

- 1075 We curated a comprehensive dataset comprising 122 pregnancy-related phenotypes
- 1076 from 120,579 Chinese pregnant women. We conducted an in-depth analysis of the
- 1077 genetic architecture underlying these phenotypes, identified biological pathways
- 1078 enriched for genetic variants, and explored genetic variants associated with alterations
- 1079 in the longitudinal trajectories of these phenotypes. Additionally, we investigated
- 1080 potential causal relationships between gestational phenotypes and various diseases.
- 1081

#### <sup>1082</sup>**Figure 2. Genetic associations with nine categories of gestational**

#### <sup>1083</sup>**phenotypes.**

- 1084 The top-left inset presents a histogram depicting the number of loci associated with
- 1085 gestational phenotypes for each trait, categorized into novel and known loci. In the
- 1086 main panel, a Fuji plot illustrates the results of the genome-wide association analysis
- <sup>1087</sup>(GWAS) across all phenotypes within nine categories. Independent variants identified
- 1088 through meta-analysis (P $\Box$ < $\Box$ 4.1 $\Box$ × $\Box$ 10<sup>-10</sup>) are shown. The number of associated
- 1089 phenotypes per pleiotropic locus is represented by filled colored boxes, with
- 1090 functional and newly discovered loci labeled directly on the plot. Detailed information
- 1091 on functional loci can be found in Supplementary Table 15. Pleiotropic and trait-
- 1092 specific associations are distinguished by circles of varying sizes. The order of the 88
- 1093 gestational phenotypes in both the histogram and Fuji plot corresponds to that in
- 1094 Supplementary Table 2.
- 1095
- <sup>1096</sup>**Figure 3. Classification of the genetic effects of SNPs on gestational**
- <sup>1097</sup>**phenotypes and Taiwan Biobank phenotypes, along with the**
- <sup>1098</sup>**identification of pathways enriched for pregnancy specific and**
- <sup>1099</sup>**general variants.**

1100 Panel **A** presents a plot classifying the genetic effects of SNPs (P $\Box$ < $\Box$ 4.1 $\Box$ × $\Box$ 10<sup>-10</sup>, <sup>1101</sup>Bonferroni correction threshold) on gestational phenotypes, utilizing a Bayesian 1102 classification algorithm and colocalization analysis. Panel **B** features a butterfly bar 1103 plot illustrating the top 20 most significant pathways for pregnancy-specific variants, 1104 identified through Metascape enrichment analysis. On the left side, the plot shows the 1105 enrichment *P* values for pregnancy-specific variants and the percentage of genes 1106 enriched in each pathway relative to the total number of pregnancy-specific genes. 1107 The right side displays the corresponding results for general variants. Pathways 1108 showing significant differences in gene enrichment, as determined by a chi-square test,

1109 are marked with an asterisk  $(*)$ .

1110

## <sup>1111</sup>**Figure 4. Results of trajectory changes in blood cell traits during**

<sup>1112</sup>**pregnancy.** 

1113 Panel **A** presents forest plots illustrating the genetic effects across five time periods 1114 with significant genetic and environmental interactions for the first 25 variants, as 1115 well as for at least two of the five periods where no overlap in genetic effects was 1116 observed. Different colors represent each period, indicating beta values and 95% 1117 confidence intervals, with annotations highlighting whether the variant has a P-value 1118 less than  $5\Box \times \Box 10^{-8}$ . The eQTL status of each variant is indicated adjacent to the 1119 variant label. Detailed information can be found in Supplementary Table 31. Panel **B** 1120 depicts changes in white blood cell (WBC) counts across the first, second, and third 1121 trimesters, at delivery, and during the postpartum period, based on data from two 1122 hospitals. A generalized additive model was used to smooth the curve, with the ribbon 1123 around the curve representing the 95% confidence interval. The first trimester spans 1124 from conception to 14 weeks (98 days), the second trimester covers weeks 14 through <sup>1125</sup>28 (196 days), and the third trimester extends from week 28 to delivery. Panel **<sup>C</sup>** 1126 displays a forest plot of the genetic effect of the rs2270401-A allele at  $17q21.1$ <sup>1127</sup>(*MED24*) on WBC counts, based on a meta-analysis across the first, second, and third



- 1129 error bars indicating the 95% confidence interval. Panel **D** presents the results of
- 1130 enrichment analyses for variants showing significant and non-significant genetic and
- 1131 environmental interactions.
- 1132 BASO: basophil absolute value; BASO\_P: basophil percentage; HGB: hemoglobin
- 1133 level; MCV: mean corpuscular volume; MCH: mean corpuscular hemoglobin;
- 1134 RDW\_CV: red blood cell volume distribution width variation; PLT: platelet count;
- 1135 MPV: mean platelet volume; PCT: platelet crit; PDW: platelet distribution width;
- 1136 P\_LCR: platelet-large cell ratio.
- 1137

### <sup>1138</sup>**Figure 5. Causal inferences between pregnancy-related phenotypes**

### <sup>1139</sup>**and BBJ phenotypes.**

- 1140 Panel A displays bidirectional Mendelian Randomization (MR) estimates, illustrating
- 1141 causal links between all pregnancy-related phenotypes (blue nodes) and traits from
- 1142 the Biobank Japan (BBJ) cohort (red nodes). Arrows indicate the direction of
- 1143 association, with red denoting an increasing effect and blue representing a decreasing
- 1144 effect. Panel **B** features a heatmap of MR results, showing nine categories of
- 1145 gestational phenotypes as the exposures (right) and BBJ phenotypes as the outcomes
- 1146 (bottom). Relationships with *P* values below the false discovery rate (FDR) threshold
- 1147 are annotated with an asterisk  $(*, q \square \le \square 0.01)$ . Panel **C** presents an MR scatterplot
- 1148 where maternal triglyceride (TG) levels serve as the exposure and the use of
- 1149 antithrombotic agents in the BBJ cohort as the outcome. Panel **D** shows an MR
- 1150 scatterplot with maternal oral glucose tolerance test 1-hour plasma glucose (OGTT1H)
- 1151 levels as the exposure, and peripheral artery disease in the BBJ cohort as the outcome.









**pregnancy% general% uncertain%**



**−LogP of general variants**

**8%**





**1st Trimester** 2nd Trimester 3rd Trimester Delivery **Postpartum Period Significant (***p***<5** × **10−8) Non−significant**

**× 10**







